Primary Catalyst Driving Colorectal Cancer Molecular Diagnostics Market Evolution in 2025: Rising Incidence Of Inflammatory Bowel Diseases (IBD) Sparks Growth In Colorectal Cancer Molecular Diagnostic Market Driver

What market dynamics are playing a key role in accelerating the growth of the colorectal cancer molecular diagnostics market?
The rise in cases of inflammatory bowel diseases (IBD), which are chronic gastrointestinal disorders that cause inflammation in the digestive tract, especially the colon and rectu*m, is expected to boost the colorectal cancer molecular diagnostic market's growth. Inflammatory bowel diseases, whose symptoms include abdominal pain, diarrhea, and weight loss, necessitate precise, efficient, and superior diagnostic solutions. The increasing cases stimulate the need for these solutions as the systemic therapy for colorectal cancer (CRC) hinges predominantly on the outcomes gathered from the molecular evaluation of the tumor. For example, research by Crohn's & Colitis UK, in 2022, discovered that the number of people in the UK living with inflammatory bowel disease (IBD) was 500,000, almost twice the previous estimates, as per the information shared by the UK Parliament in April 2024. Consequently, escalating cases of inflammatory bowel diseases (IBD) will fuel the colorectal cancer molecular diagnostic market's growth. Furthermore, the colorectal cancer molecular diagnostics market is expected to burgeon due to the escalating prevalence of colorectal cancer, a disease affecting the colon or rectu*m, which form a part of the digestive system. Colorectal cancer results when cells within the colon or rectu*m proliferate uncontrollably to form a tumor. The rise in colorectal cancer necessitates increased demand for molecular diagnostics for detecting and treating cancer. For instance, the American Cancer Society, a US-based volunteer health organization committed to eradicating cancer, revealed in March 2023 that an estimated 153,020 individuals are likely to be diagnosed with colorectal cancer (CRC). Out of this number, about 52,550 people are expected to succumb to the disease, with 19,550 cases and 3,750 deaths occurring among individuals under the age of 50. Therefore, the rapid increase in colorectal cancer incidence is propelling the expansion of the colorectal cancer molecular diagnostics market.

Get Your Colorectal Cancer Molecular Diagnostics Market Report Here:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

How will the growth rate of the colorectal cancer molecular diagnostics market shape industry trends by 2034?
The market size of colorectal cancer molecular diagnostics has seen substantial growth in the past few years. The expected growth from $2.56 billion in 2024 to $2.77 billion in 2025 is a compound annual growth rate (CAGR) of 8.1%. The growth observed in the historic period is due to the increasing numbers of colorectal cancer cases, heightened awareness and screening initiatives, a growing focus on personalized medicine, and governmental cancer control strategies.

The market size for molecular diagnosis of colorectal cancer is projected to undergo substantial increase in the coming years, eventually reaching $3.79 billion in 2029 with an 8.1% compound annual growth rate (CAGR). Factors contributing to this expected growth during the projection period includes a rise in aging population along with growing risk elements, incorporation of genomic data into medical procedures, an upswing in the use of precision medicine, and worldwide initiatives in cancer research and collaboration. Important trends in this forecast period comprise a heightened focus on early detection markers, incorporation of artificial intelligence (AI) in data interpretation, a surge in circulating tumor DNA (CTDNA) analysis, the growth of companion diagnostics for targeted treatments, and a focus on immunotherapy markers.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

What are the most significant trends transforming the colorectal cancer molecular diagnostics market today?
Prominent companies in the colorectal cancer molecular diagnostic market are concentrating on the creation of innovative molecular diagnostics and personalized healthcare solutions, such as the Shield Blood Test, which aids in the early identification of colorectal cancer when it's more manageable. The Shield Blood Test is a preliminary examination designed for the early detection of colorectal cancer (CRC). In May 2022, for example, Guardant Health, a biotechnology firm based in the United States that provides molecular diagnostic products for cancer, introduced its Shield Blood Test. The susceptible shield test offers an easy screening method involving a straightforward blood draw to address difficulties associated with patients' willingness to be screened. The test demonstrated a 91% sensitivity for colorectal cancer detection and 20% for the detection of advanced adenomas, with a specificity score of 92%. The Shield test uses information from diverse cohorts of over 2,000 colorectal cancer patients, 357 with advanced adenoma, and 3,757 healthy individuals to detect early signs of colorectal cancer in the blood.

Which primary segments of the colorectal cancer molecular diagnostics market are driving growth and industry transformations?
The colorectal cancer molecular diagnostics market covered in this report is segmented -

1) By Type: Instruments, Reagents And Kits, Services
2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings

Subsegments:
1) By Instruments: PCR Machines, Sequencers, Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs
3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120

Which geographical regions are pioneering growth in the colorectal cancer molecular diagnostics market?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the influential players reshaping the colorectal cancer molecular diagnostics market landscape?
Major companies operating in the colorectal cancer molecular diagnostics market report are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

What Is Covered In The Colorectal Cancer Molecular Diagnostics Global Market Report?

• Market Size Forecast: Examine the colorectal cancer molecular diagnostics market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the colorectal cancer molecular diagnostics market for a structured understanding.
• Key Players Overview: Analyze major players in the colorectal cancer molecular diagnostics market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the colorectal cancer molecular diagnostics market.
• Segment Contributions: Evaluate how different segments drive overall growth in the colorectal cancer molecular diagnostics market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the colorectal cancer molecular diagnostics market.
• Industry Challenges: Identify potential risks and obstacles affecting the colorectal cancer molecular diagnostics market.
• Competitive Landscape: Review strategic developments in the colorectal cancer molecular diagnostics market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.